The market research firm credits insurance coverage with lifting uptake in Canada, though it gives no Canadian figures. It also says the Wegovy pill passed 3m US prescriptions in about five months.
Recap by typeshit. Full story at Benefits and Pensions Monitor.
Ireland's drug pricing body recommended semaglutide over tirzepatide for cost reasons, and Higgins says it's the right call, with a pun he didn't get to use.
Costco is adding Novo Nordisk's semaglutide shots to what it offers. Details are thin here, so tap through for how pricing and access will work.
Avi Roy puts last year's sales of the two shots at $71B, roughly four times the $18B he says the two AI labs brought in.
An explainer on talking to a provider about whether Wegovy fits you, plus a reminder that insurance may not pay for it.
Nurturher Aesthetics points out retatrutide has not been FDA approved and explains why most providers are not taking it themselves.
Spierings explains why the placebo effect makes skincare hard to study, in a clip from the show's full collagen peptides episode.
Loading…